Building Your Care Team and Long-Term Monitoring
At a Glance
People with Ghosal hematodiaphyseal dysplasia need an individualized, coordinated plan that tracks blood counts, bone changes, movement, and the effects of long-term steroids, including bone strength and adrenal function.
Because Ghosal hematodiaphyseal dysplasia (GHDD) is a lifelong condition that affects both the blood and the bones, managing it requires a specialized team and a proactive monitoring plan. While GHDD is ultra-rare and there is no “standard” schedule, care will focus on balancing effective treatment with the management of long-term side effects [1][2].
Building Your Care Team
A “multidisciplinary” approach—where different specialists work together—is essential for a patient with GHDD. Your team will likely include:
- Hematologist (Pediatric or Adult): The primary doctor for managing anemia, marrow fibrosis, transfusion needs, and iron overload tracking [2][3].
- Skeletal Dysplasia Specialist or Geneticist: To monitor bone changes and provide guidance on the long-term progression of the diaphyseal changes [2][4].
- Endocrinologist or Rheumatologist: Essential if treated with long-term corticosteroids to monitor growth, bone health, and adrenal function [5][6].
- Orthopedist: To assess limb alignment, gait (walking) disturbances, and manage any physical deformities like bowing [3][1].
Routine Monitoring and Labs
Monitoring is individualized based on symptoms and current treatment. Common tests include:
1. Blood Work
- Complete Blood Count (CBC) and Reticulocytes: Used to track hemoglobin, platelets, and white blood cells. This helps determine if the current treatment is maintaining healthy blood levels or if a transfusion is needed [2][7].
- Inflammatory Markers (CRP and ESR): These tests measure systemic inflammation. While sometimes used, they are nonspecific and may be normal in GHDD or lowered by steroids independently of marrow improvement; they are not established stand-alone measures of treatment response [8][9].
2. Imaging
Managing Long-Term Steroid Use
If treated with chronic corticosteroids, the focus shifts to minimizing side effects while maintaining the benefits. You will need a written schedule for medications and emergency contacts.
- Growth and Weight: Steroids can slow growth velocity and cause weight gain. The team will track height, weight, glucose, and blood pressure closely [5][10].
- Bone Density (DEXA): Long-term steroids can ironically weaken the “quality” of bone (osteoporosis) even while GHDD makes the bones look thicker on X-rays. Bone density scans (DEXA) may be considered but require careful skeletal-dysplasia-aware interpretation [5][11].
- Adrenal Health: Prolonged steroid use can cause the body to stop making its own natural cortisol (adrenal suppression). You must have a clear sick-day/stress-dose and medical alert plan for serious illness. If steroids are ever stopped or tapered, it must be done very slowly under a doctor’s guidance to prevent a crisis [6][12].
Quality of Life and Functional Support
Beyond the labs, day-to-day well-being is the most important metric.
- Functional Assessments: At every visit, the team should evaluate gait, walking endurance, and any reported bone pain [3][1]. If walking becomes difficult, physical therapy or orthotic supports may be helpful.
- Psychological Impact: Frequent blood draws and X-rays can lead to “lab anxiety” or “scan anxiety.” Preparing with age-appropriate explanations and involving psychosocial support specialists can help make these visits less stressful.
By staying consistent with an individualized monitoring plan, you can catch changes early and adjust treatments to remain active and healthy.
Common questions in this guide
Which specialists should be involved in care for GHDD?
What blood tests are used to monitor Ghosal hematodiaphyseal dysplasia?
How are bone changes and steroid-related bone problems monitored in GHDD?
What precautions are needed if a person with GHDD takes steroids long term?
How can daily function and emotional well-being be supported with GHDD?
One line in your results can change your plan.
A complete blood count can help decide if current treatment is keeping blood levels stable or if a transfusion is needed. We check your results against the latest research to help you prepare for what’s next.
Get notified when new evidence is published on Ghosal hematodiaphyseal dysplasia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (12)
- 1
Insights into Natural History, Phenotypic, and Molecular Spectrum in a Large Cohort of Osteosclerotic Disorders.
Uludağ Alkaya D, Usluer E, Alp Ünkar Z, et al.
Calcified tissue international 2025; (116(1)):59 doi:10.1007/s00223-025-01366-w.
PMID: 40198394 - 2
Novel compound heterozygous variants of TBXAS1 presenting with Ghosal hematodiaphyseal dysplasia treated with steroids.
Kim SY, Ing A, Gong S, et al.
Molecular genetics & genomic medicine 2021; (9(3)):e1494 doi:10.1002/mgg3.1494.
PMID: 33595912 - 3
Steroid-responsive anemia with bony dysplasias: What lurks behind!
Khandelwal S, Khurana R, Kanvinde P, et al.
Journal of tropical pediatrics 2024; (70(5)) doi:10.1093/tropej/fmae028.
PMID: 39277773 - 4
Ghosal Type Hematodiaphyseal Dysplasia.
Jeevan A, Doyard M, Kabra M, et al.
Indian pediatrics 2016; (53(4)):347-8 doi:10.1007/s13312-016-0851-y.
PMID: 27156553 - 5
A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis.
Yu SH, Drucker AM, Lebwohl M, Silverberg JI
Journal of the American Academy of Dermatology 2018; (78(4)):733-740.e11 doi:10.1016/j.jaad.2017.09.074.
PMID: 29032119 - 6
Glucocorticoid treatment and adrenal suppression in children: current view and open issues.
Improda N, Chioma L, Capalbo D, et al.
Journal of endocrinological investigation 2025; (48(1)):37-52 doi:10.1007/s40618-024-02461-9.
PMID: 39352628 - 7
Middle-aged women with hematodiaphyseal dysplasia: Ghosal syndrome: Case report.
Ravikumar DB, Sivasubramanian BP, Thungala S, et al.
Radiology case reports 2024; (19(10)):4578-4582 doi:10.1016/j.radcr.2024.07.028.
PMID: 39220787 - 8
TBXAS1 deficiency causes autoinflammation responsive to IL-6 inhibitor.
Liu L, Wang J, Ding Y, et al.
Annals of the rheumatic diseases 2026; (85(4)):704-714 doi:10.1016/j.ard.2025.09.014.
PMID: 41162285 - 9
Ghosal Hematodiaphyseal Dysplasia: A Case Report With Review of Genetically Confirmed Cases.
Dikme G, Karkucak M, Topçu FS, Bozkurt C
Journal of pediatric hematology/oncology 2026; (48(5)):e189-e195 doi:10.1097/MPH.0000000000003208.
PMID: 42059562 - 10
Glucocorticoid prescribing in neurology.
Jones AP, Debono M, Walsh J, et al.
Practical neurology 2024; (24(4)):289-295 doi:10.1136/pn-2023-003855.
PMID: 38553045 - 11
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.
Buckley L, Guyatt G, Fink HA, et al.
Arthritis care & research 2017; (69(8)):1095-1110 doi:10.1002/acr.23279.
PMID: 28585410 - 12
Frequency and Duration of Adrenal Suppression Following Glucocorticoid Therapy in Children With Rheumatic Diseases.
Ahmet A, Brienza V, Tran A, et al.
Arthritis care & research 2017; (69(8)):1224-1230 doi:10.1002/acr.23123.
PMID: 27723273
This page is for informational purposes only and does not replace medical advice. Your GHDD care team should individualize monitoring, steroid plans, and emergency instructions for your situation.